Whanin Pharm (016580) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Whanin Pharm (016580) has a cash flow conversion efficiency ratio of 0.022x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩9.26 Billion ≈ $6.28 Million USD) by net assets (₩425.47 Billion ≈ $288.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Whanin Pharm market capitalisation for the company's overall valuation and market capitalisation.
Whanin Pharm - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Whanin Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Whanin Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Whanin Pharm ranked by their cash flow conversion efficiency. Explore 016580 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Norsk Titanium AS
OL:NTI
|
-0.732x |
|
Dat Phuong JSC
VN:DPG
|
0.059x |
|
Military Insurance Corp
VN:MIG
|
N/A |
|
ZenaTech Inc.
NASDAQ:ZENA
|
-0.230x |
|
Aurskog Sparebank
OL:AURG
|
0.070x |
|
Kopla Co. Ltd
KQ:126600
|
-0.039x |
|
TEN Holdings, Inc. Common Stock
NASDAQ:XHLD
|
-0.249x |
|
NMP Acquisition Corp.
NASDAQ:NMP
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Whanin Pharm (2009–2025)
The table below shows the annual cash flow conversion efficiency of Whanin Pharm from 2009 to 2025. View current stock price of Whanin Pharm for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩421.01 Billion ≈ $285.31 Million |
₩9.04 Billion ≈ $6.13 Million |
0.021x | -60.97% |
| 2024-12-31 | ₩376.00 Billion ≈ $254.81 Million |
₩20.69 Billion ≈ $14.02 Million |
0.055x | -15.01% |
| 2023-12-31 | ₩358.21 Billion ≈ $242.75 Million |
₩23.20 Billion ≈ $15.72 Million |
0.065x | +28.33% |
| 2022-12-31 | ₩333.93 Billion ≈ $226.30 Million |
₩16.85 Billion ≈ $11.42 Million |
0.050x | -54.67% |
| 2021-12-31 | ₩317.23 Billion ≈ $214.98 Million |
₩35.32 Billion ≈ $23.93 Million |
0.111x | +45.12% |
| 2020-12-31 | ₩296.60 Billion ≈ $201.00 Million |
₩22.75 Billion ≈ $15.42 Million |
0.077x | -14.86% |
| 2019-12-31 | ₩274.46 Billion ≈ $186.00 Million |
₩24.73 Billion ≈ $16.76 Million |
0.090x | +34.01% |
| 2018-12-31 | ₩259.58 Billion ≈ $175.92 Million |
₩17.45 Billion ≈ $11.83 Million |
0.067x | -30.39% |
| 2017-12-31 | ₩243.08 Billion ≈ $164.73 Million |
₩23.48 Billion ≈ $15.91 Million |
0.097x | +7.26% |
| 2016-12-31 | ₩220.13 Billion ≈ $149.18 Million |
₩19.82 Billion ≈ $13.43 Million |
0.090x | -30.67% |
| 2012-12-31 | ₩162.53 Billion ≈ $110.14 Million |
₩21.11 Billion ≈ $14.31 Million |
0.130x | +28.78% |
| 2011-12-31 | ₩149.85 Billion ≈ $101.55 Million |
₩15.12 Billion ≈ $10.24 Million |
0.101x | -41.22% |
| 2009-12-31 | ₩108.44 Billion ≈ $73.49 Million |
₩18.61 Billion ≈ $12.61 Million |
0.172x | -- |
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more